Ryan White Care Hepatitis C & B Language
NATAP Webinars
Aging in Women Living with HIV
Friday, October 18h, 2024 - 12:30pm
Click here to Register
View all archived NATAP webinars here
Current HIV Articles and News Updates
HIV
ID Week:
Week 48 Results of a Phase 2 Study Evaluating Once-weekly Oral Islatravir Plus Lenacapavir
- (10/20/24)
 
More HIV Articles...
Hepatitis D
HEPATITIS D INFECTION: who should be screened AASLD 2018 HBV Guidelines
 
EASL:
Robust reduction of HBsAg and HDV RNA levels with low risk for ALT elevations in JNJ-73763989 treated patients with chronic hepatitis D (CHD) and baseline HBsAg levels below 10,000 IU/mL: Part 2 of the REEF-D study
- (06/18/24)
 
More Hep D Articles...
 
Aging & Perinatally Acquired HIV
 
HIV reservoir and premature aging: risk factors for aging-associated illness in adolescents and young adults with perinatally acquired HIV
- (09/25/24)
 
More Aging & HIV Articles...
 
PrEP
 
ID Week:
Trajectories of Newly Initiated Pre-Exposure Prophylaxis (PrEP) Use among Priority Populations with Unmet Needs for PrEP in the USA
- (10/21/24)
 
ID Week:
Real-World Use of Cabotegravir Long-Acting for Pre-Exposure Prophylaxis: Data from Trio Health Cohort
- (10/21/24)
 
ID Week:
Missed opportunities for HIV Prevention and Treatment in People Hospitalized with Serious Injection Related Infections: The CHOICE+ Cohort
- (10/21/24)
 
ID Week:
Week 26 Interim Analysis of Implementation and Delivery of Long-Acting Injectable Cabotegravir for PrEP in a Community Pharmacy Setting
- (10/21/24)
 
ID Week:
Cabotegravir Long-Acting for Pre-Exposure Prophylaxis (PrEP): Real World Data on On-Time Dosing, HIV Testing and HIV Acquisition from the OPERA Cohort
- (10/21/24)
 
ID Week:
Social Determinants of Health and Side Effects Significantly Predict Pre-Exposure Prophylaxis (PrEP) Preferences for Every 2 Month Long-Acting Injectable vs. Daily Oral PrEP among Cisgender Women in the United States and the Dominican Republic
- (10/21/24)
 
ID Week:
Change in Healthcare Professionals' Identification, Counseling, and Adherence With Black Women for Long-Acting Cabotegravir (CAB LA) for PrEP Across Women's Health, Primary Care, and Infectious Diseases Sites: Findings From the EBONI Study
- (10/21/24)
 
ID Week:
PrEP Decision Factors: a CHORUS Healthcare Professional Survey
- (10/21/24)
 
ID Week:
Changes in Renal Function After Switching from Emtricitabine/Tenofovir Disoproxil Fumarate to Emtricitabine/Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis (PrEP): A Real-World Study
- (10/21/24)
 
ID Week:
Update on Lenacapavir for PrEP: Results from the Interim Analyses of PURPOSE 1 and PURPOSE 2
- (10/21/24)
 
ID Week:
Over 80% Adhere to Long-Acting CAB+RPV Despite Prior Non-Adherence
- Mark Mascolini (10/21/24)
 
ID Week:
People With HIV in the United States (US) Switching to Cabotegravir + Rilpivirine Long-Acting (CAB+RPV LA) From Oral Antiretroviral Therapy (ART) Have Numerous Real-World Benefits, Including High Adherence and Treatment Satisfaction
- (10/21/24)
 
ID Week:
Long-acting Injectable HIV Treatment in Individuals with Adherence Challenges:
- (10/21/24)
 
More PreP Articles...
Current Hepatitis C and B Articles
Hepatitis C
CBO Issues Paper: "A Call for New Research in the Area of Hepatitis C" creates inordinate barrier to HCV elimination
- (08/06/24)
 
CBO Statement: "Budgetary Effects of Policies That Would Increase Hepatitis C Treatment", creates impossible unique barrier to eliminate HCV
- (08/06/24)
 
Hepatitis C Virus Reinfection Among Men Who Have Sex With Men With HIV in New York City
- (08/02/24)
 
IAS:
HCV incidence among MSM using HIV PrEP and MSM with HIV in a New York City Health Care System over 2 decades
- (08/02/24)
 
IAS:
Community-Based HCV Self-Testing Widens Testing Access in Big Vietnam Study
- Mark Mascolini (07/27/24)
 
Medicaid Expansion and Restriction Policies for Hepatitis C Treatment
- (07/20/24)
 
More Hep C Articles...
Hepatitis B
HBV Patient Declaration of Rights
-
 
ID Week:
Optimizing 2-Drug Switch HBV Screening: pilot intervention to increase HBV screening
- (10/20/24)
 
GSK receives US FDA Fast Track designation for bepirovirsen in chronic hepatitis B
- (08/12/24)
 
IAS:
Efficacy of dolutegravir/lamivudine (DTG/3TC) in adults with HIV-1 and isolated reactive hepatitis B core antibody (anti-HBc): results from the phase 3/3b GEMINI-1/-2, STAT, TANGO, and SALSA
- (07/31/24)
 
Long-term Hepatitis B and Liver Outcomes Among Adults Taking Tenofovir-Containing Antiretroviral Therapy for HBV/HIV Coinfection in Zambia - encourages earlier treatment in HBV monoinfection
- (07/10/24)
 
More Hep B Articles...
 
Fatty Liver, NAFLD, NASH
 
2nd New Fatty Liver Drug Pegozafermin in Phase 3
- (08/04/24)
 
Phase 3 Efuxifermin Fatty Liver/MASH Trial Ongoing; EASL 96 weeks HARMONY phase 2b study Results
- (08/04/24)
 
Steatotic liver disease and HIV: an agenda for 2030: 'PWH should be screened for fatty liver, steatosis'
- (07/10/24)
 
EASL:
Identification and validation of pre-identified morphological baseline features for prediction of fibrosis progression in MAESTRO-NASH
- (06/18/24)
 
More Fatty Liver Articles...
Check Out Our Special NATAP Features
List not necessarily listed here in order of date being held.
22 February 2024 - 23 February 2024 Nairobi Kenya
https://academicmedicaleducation.com/meeting/african-workshop-hiv-women-2024
May 2-4, 2024 Atlanta, GA
https://acthiv.org/acthiv-2024-program/
https://ddw.org/
https://easl.eu/event/easl-congress-2024/
https://asm.org/Events/ASM-Microbe/Home
Munich, Germany, and virtually from 22 to 26 July 2024.
Pre-conferences will be held on 20 and 21 July.
https://www.iasociety.org/conferences/aids2024
Conference on Liver Disease in Africa (COLDA) 2024
19 September 2024 - 21 September 2024 Egypt
https://academicmedicaleducation.com/meeting/conference-liver-disease-africa-colda-2024
18 September 2024 - 20 September 2024 Liverpool, United Kingdom
https://academicmedicaleducation.com/meeting/international-workshop-clinical-pharmacology-hiv-hepatitis-and-other-antiviral-drugs-2024
https://www.iasociety.org/conferences/hivr4p2024/registration
https://idweek.org/#
24 October 2024 - 25 October 2024 United States
Washington DC, United States
https://academicmedicaleducation.com/meeting/international-workshop-hiv-aging-2024
10-13 November 2024
https://hivglasgow.org/
San Diego, California
https://www.aasld.org/liver-meeting-tlm-2024
https://informedhorizonseducation.com/hiv-respidart-2024